PortfoliosLab logoPortfoliosLab logo
ISIN
US45337C1027
CUSIP
45337C102
IPO Date
Nov 4, 1993

Highlights

Market Cap
$20.27B
Enterprise Value
$16.84B
EPS (TTM)
$7.06
PE Ratio
13.89
PEG Ratio
0.01
Total Revenue (TTM)
$5.36B
Gross Profit (TTM)
$3.76B
EBITDA (TTM)
$1.80B
Year Range
$66.74 - $112.29
Target Price
$108.90
ROA (TTM)
19.51%
ROE (TTM)
25.46%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

INCY Performance Chart

Incyte Corporation (INCY) is down 0.8% since the beginning of the year. At $98 per share, INCY is trading 12.7% below its 52-week high of $112. Investors who bought $1,000 worth of INCY shares 5 years ago would now be looking at an investment worth $1,176.


Loading charts...

S&P 500 Index

Returns By Period

Incyte Corporation (INCY) has returned -0.80% so far this year and 46.00% over the past 12 months. Over the last ten years, INCY has returned 1.44% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.


Incyte Corporation

1D
6.22%
1M
0.86%
YTD
-0.80%
6M
-3.47%
1Y
46.00%
3Y*
16.14%
5Y*
3.29%
10Y*
1.44%

Benchmark (S&P 500 Index)

1D
-0.74%
1M
4.90%
YTD
10.35%
6M
10.28%
1Y
26.52%
3Y*
20.83%
5Y*
12.30%
10Y*
13.66%
*Multi-year figures are annualized to reflect compound growth (CAGR)

INCY Monthly Returns History

Based on dividend-adjusted daily data since Nov 4, 1993, INCY's average daily return is +0.13%, while the average monthly return is +2.64%. At this rate, an investment would double in approximately 2.2 years.

Historically, 53% of months were positive and 47% were negative. The best month was Feb 2000 with a return of +151.0%, while the worst month was Mar 2000 at -68.3%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.

On a daily basis, INCY closed higher 48% of trading days. The best single day was Jan 3, 2000 with a return of +49.4%, while the worst single day was Sep 28, 2005 at -41.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20261.32%1.20%-7.06%1.22%1.54%1.28%-0.80%
20257.37%-0.89%-17.62%3.48%3.83%4.67%9.97%12.98%0.24%10.22%11.75%-5.45%43.00%
2024-6.40%-0.70%-2.38%-8.64%11.03%4.90%7.34%0.91%0.67%12.13%0.63%-7.40%10.00%
20236.00%-9.58%-6.12%2.96%-17.28%1.14%2.36%1.27%-10.48%-6.65%0.76%15.55%-21.83%
20221.27%-8.11%16.28%-5.62%1.24%0.11%2.25%-9.33%-5.38%11.55%7.17%0.82%9.43%
20213.18%-12.36%3.32%5.06%-1.87%0.42%-8.06%-1.11%-10.08%-2.62%1.10%8.39%-15.61%

Benchmark Metrics

Incyte Corporation has an annualized alpha of 20.29%, beta of 1.26, and R2 of 0.14 versus S&P 500 Index. Calculated based on daily prices since November 05, 1993.

  • This stock captured 148.80% of S&P 500 Index gains and 126.02% of its losses - amplifying both gains and losses, but participating more in upside than downside.
  • R2 of 0.14 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
20.29%
Beta
1.26
0.14
Upside Capture
148.80%
Downside Capture
126.02%

Return for Risk

Risk / Return Rank

INCY ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


INCY Risk / Return Rank: 7878
Overall Rank
INCY Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
INCY Sortino Ratio Rank: 7878
Sortino Ratio Rank
INCY Omega Ratio Rank: 7575
Omega Ratio Rank
INCY Calmar Ratio Rank: 7979
Calmar Ratio Rank
INCY Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Incyte Corporation (INCY) and compare them to S&P 500 Index.


INCYBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

1.41

2.24

-0.83

Sortino ratio

Return per unit of downside risk

2.14

3.07

-0.93

Omega ratio

Gain probability vs. loss probability

1.26

1.41

-0.14

Calmar ratio

Return relative to maximum drawdown

2.52

2.93

-0.41

Martin ratio

Return relative to average drawdown

5.66

13.52

-7.86

Dividends

Dividend History


Incyte Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Incyte Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Incyte Corporation was 98.54%, occurring on Mar 9, 2009. Recovery took 2016 trading sessions.

The current Incyte Corporation drawdown is 35.82%.


Related event

Drawdown

Fall

Recovery

Underwater

Financial crisis2007–2009
-98.54%Mar 2009
9y 12d8y 3d
17y 15dFeb 2000 - Mar 2017
1999 bear market1999
-67.13%Oct 1999
1y 8mo2mo 19d
1y 10moFeb 1998 - Dec 1999
2024 bear market2024
-66.47%Apr 2024
7y 1mo
9y 2moMar 2017 - now
1997 bear market1997
-41.98%Apr 1997
2mo 9d4mo 18d
6mo 27dFeb 1997 - Sep 1997
1994 bear market1994
-38.89%Apr 1994
2mo 8d7mo 15d
9mo 23dFeb 1994 - Dec 1994

Drawdown Indicators


INCYBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-98.54%

-56.78%

-41.76%

Max Drawdown (1Y)

Largest decline over 1 year

-18.33%

-9.10%

-9.23%

Max Drawdown (3Y)

Largest decline over 3 years

-33.83%

-18.90%

-14.93%

Max Drawdown (5Y)

Largest decline over 5 years

-41.53%

-25.43%

-16.10%

Max Drawdown (10Y)

Largest decline over 10 years

-66.47%

-33.92%

-32.55%

Current Drawdown

Current decline from peak

-35.82%

-0.74%

-35.08%

Average Drawdown

Average peak-to-trough decline

-59.92%

-10.72%

-49.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.14%

1.97%

+6.17%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Incyte Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Incyte Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for INCY, comparing it with other companies in the Biotechnology industry. Currently, INCY has a P/E ratio of 13.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for INCY compared to other companies in the Biotechnology industry. INCY currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for INCY relative to other companies in the Biotechnology industry. Currently, INCY has a P/S ratio of 3.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for INCY in comparison with other companies in the Biotechnology industry. Currently, INCY has a P/B value of 3.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with INCY

Add Incyte Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with INCY